The positive interim Phase I data evaluating a new oral formulation of SMT C1100 for Duchenne Muscular Dystrophy (DMD) is extremely encouraging and supports the potential development of an improved formulation. Full data from the Phase I trial is expected in due course. SMT C1100, the group’s lead utrophin modulator programme for DMD, received approval to initiate a Phase II proof of concept clinical trial, PhaseOut DMD, in January and we expect data from the first group of patients from H2 2016 ....
